The Rare Treatment Accelerator (RTA) is Healx’s partnering programme for academic groups, patient groups and early-stage biotechs who have drug redevelopment opportunities for rare disease, but who need additional financial support or clinical expertise to take the assets to clinical trial. Working with successful partners, Healx will apply its drug development and clinical expertise, as well as its financial resources, to move these assets to trial.

Application criteria

To take part in the RTA, applicants should have drug redevelopment projects for rare diseases with a current unmet medical need, known natural history and ideally, established clinical trial endpoints or biomarkers. The opportunity would preferably be preclinically-validated in models that are representative of the rare disease of interest and have a clear scientific rationale. 

Apply to the RTA

Applications for this RTA cycle are open now. If you are interested in applying, please click ‘Apply’ below to be taken to our eligibility form. This form will help us determine whether your drug redevelopment opportunity aligns with our requirements and should take no longer than 30 minutes to complete. You can also see a preview of the questions here.

For more information on the RTA, please read our blog or visit our RTA webpage.

This questionnaire should take <30 minutes to complete. 

At this stage, please only share non-confidential data.  Your responses will be auto-saved as you go, so you do not need to complete the form in one sitting. Please manually save on a regular basis, just in case.

The eligibility questionnaire is the FIRST step of the RTA process, if invited to progress, we will send you the full application form to complete.

For more information on the RTA, please read our blog or visit the RTA webpage on our website.